NuCana's New Findings on NUC-7738
NuCana plc (NASDAQ: NCNA) recently showcased compelling clinical data about NUC-7738 at the renowned European Society for Medical Oncology (ESMO) Immuno-Oncology Congress. This latest presentation marked an important milestone for the company as it highlights new advancements in the treatment of patients with PD-1-resistant melanoma.
Promising Clinical Activity
The data reveals that patients with metastatic melanoma, who previously showed resistance to PD-1 inhibitors, have demonstrated significant clinical activity when treated with NUC-7738 in conjunction with pembrolizumab. Remarkably, all participants had progressive disease prior to receiving this innovative treatment.
Clinical Results Overview
In the ongoing study, two patients achieved partial responses, one of which was confirmed, while seven patients maintained stable disease. One particularly notable case showed an ongoing stable disease evolving into a complete metabolic response, showcasing no detectable active disease—a promising outcome for future treatment strategies.
Study Cohorts and Safety Profile
As of the latest analysis, nine patients from the Expansion Cohort have been treated as part of the planned enrollment of up to 28 additional participants. Alongside the 12 individuals from the Dose Confirmation Cohort, the total will amount to as many as 40 patients contributing valuable data to this combination study.
Importantly, no new safety signals were reported during the study. Several patients continue to respond positively to the therapy with ongoing disease control evident, including one unconfirmed partial response and patients enjoying durable stable disease outcomes.
Support from Leadership
Hugh S. Griffith, the Founder and Chief Executive Officer of NuCana, expressed enthusiasm about the ongoing progress of this study. He stated, “The clinical activity and favorable safety profile of NUC-7738 support its potential to offer meaningful benefit for patients with advanced melanoma who have exhausted current treatment options.”
A Step Toward Clinical Advancement
Mr. Griffith further emphasized the importance of these findings as they provide a solid foundation for continued enrollment and push toward further clinical advancements. This initiative marks a crucial step towards a potential registrational pathway for NUC-7738, raising hopes for a new line of treatment for patients battling advanced melanoma.
Media Coverage and Recognition
One inspiring participant who achieved a complete metabolic response was featured in a UK Channel 4 documentary series titled Cancer Detectives: Finding the Cures. The series also highlighted Professor Sarah Blagden, the study’s lead investigator and Professor of Experimental Oncology at the University of Oxford, underscoring the significant progress being made in the field.
Details of the ESMO Presentation
The details of NuCana’s presentation during the ESMO Immuno-Oncology Congress are outlined below:
Abstract Title: A Phase 2 expansion study of NUC-7738 in combination with pembrolizumab in patients with PD-1 inhibitor-resistant cutaneous melanoma (NuTide:701)
Poster Number: 321TiP
Date: Wednesday, December 10, 2025
Presenting Author: Dr. Miranda J. Payne
About NuCana
NuCana is dedicated to enhancing treatment outcomes for cancer patients through innovative approaches. By leveraging our unique ProTide technology, we aim to improve the efficacy and safety of widely used chemotherapy agents, particularly nucleoside analogs. Our pipeline includes NUC-7738, a transformative agent affecting gene expression in cancer cells, and NUC-3373, aimed at addressing the limitations of conventional treatments.
NUC-7738 is progressing through a Phase 2 study evaluating its effectiveness both as a monotherapy for advanced solid tumors and in combination with pembrolizumab for melanoma patients. Meanwhile, NUC-3373 is under investigation in a Phase 1b/2 modular study in conjunction with other therapies, including pembrolizumab for various advanced cancers.
Frequently Asked Questions
What is NUC-7738?
NUC-7738 is an experimental anti-cancer drug developed by NuCana, designed to target cancer cells more effectively and safely than traditional treatments.
What were the recent findings presented by NuCana?
Recent findings indicated promising results for NUC-7738 in patients with PD-1-resistant melanoma, including partial responses and stable disease outcomes.
How does the ProTide technology work?
ProTide technology enhances the delivery and efficacy of nucleoside analogs, helping to achieve higher concentrations of active anti-cancer metabolites in target cells.
What is NuCana’s clinical approach?
NuCana focuses on developing novel cancer therapeutics while evaluating their performance in advanced clinical studies, aiming for higher efficacy and better patient outcomes.
How can I learn more about NuCana?
Interested individuals can reach out to NuCana directly through their official contact options for more details about their clinical trials and pipeline.
